Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
A significant fraction of chronic myeloid leukemia (CML) patients relapse from first-generation (1G) tyrosine kinase inhibitor (TKI) therapy, and this could be prevented by the de novo use of 2G TKIs. However, there are no patient stratification markers to guide clinicians in the selection of frontline TKI therapy for optimal outcomes in CML patients. Here, identical results from two independent CML cohorts indicate that the determination of NOCIVA mRNA levels by clinically approved qPCR platforms from de novo chronic phase CML patients could provide significant support for clinicians in recognizing patients in need of first-line 2G TKI therapy. In acute myeloid leukemia (AML), high NOCIVA/CIP2A ratio at diagnosis could indicate a need for first-line therapy intensification.
Recent Posts
- PFAS levels in mothers’ blood associated with children’s brain structure and function Researchers from the University of Turku and Turku University Hospital, Finland, and Örebro University, Sweden, Read moreOctober 13, 2025
- Professor Laura Elo receives award for outstanding research from the Jenny and Antti Wihuri Foundation The Jenny and Antti Wihuri Foundation awarded Professor of Computational Medicine Laura Elo a €50,000 Read moreOctober 10, 2025
- Recruit your next student at the MSc Thesis Project Expo 2025. Registration is now open! Do you supervise MSc theses in the biosciences? Join the MSc Thesis Project Expo on Read moreOctober 10, 2025
- University of Turku celebrates Professor Shimon Sakaguchi’s Nobel prize Professor Shimon Sakaguchi, winner of the 2025 Nobel Prize in Medicine, is a visiting professor Read moreOctober 7, 2025
- Heidi Isokääntä Successfully Defends Dissertation on Gut Microbiome Development Heidi Isokääntä Successfully Defends Dissertation on Gut Microbiome Deveopment Turku, 26 September 2025 – Bioanalyst Read moreSeptember 29, 2025
- University of Jyväskylä to Award Honorary Doctorate to Johanna Ivaska The University of Jyväskylä will award 11 new honorary doctorates in May 2026. One of Read moreSeptember 26, 2025